Skip to main content

Table 3 Therapy Related Changes in Outcome Measures at Each Follow up Compared to Baseline Using Linear Multilevel Regression Model

From: Clinical efficacy of various anti-hypertensive regimens in hypertensive women of Punjab; a longitudinal cohort study

Changes in Outcome Measures

3 Months

6 Months

9 Months

12 Months

β (95% CI)

p-value

β (95% CI)

p-value

β (95% CI)

p-value

β (95% CI)

p-value

Changes in SBP from baseline

 LTN

−17.88 (−20.25, − 15.50)

<  0.01**

− 17.88 (−20.25, − 15.50)

<  0.01**

−16.38 (−18.75, −14.00)

<  0.01**

−18.63 (− 21.00, − 16.25)

<  0.01**

 LTN + HCT

−25.79 (−27.25,-24.34)

<  0.01**

− 25.14 (−26.59, −23.69)

<  0.01**

−25.42 (−26.87, − 23.97)

<  0.01**

−26.45 (− 27.90, − 24.99)

<  0.01**

 N-GITS

−28.53 (−30.07, − 26.989

<  0.01**

−28.16 (−29.70, − 26.61)

<  0.01**

−29.58 (−31.12, − 28.04)

<  0.01**

−28.89 (− 30.44, − 27.35)

<  0.01**

 N-GITS + LTN + HCT

− 45.95 (− 47.92, − 43.97)

<  0.01**

− 48.88 (− 50.85, − 46.9)

<  0.01**

−49.74 (− 51.72, − 47.77)

<  0.01**

−50.17 (− 52.15, − 48.20)

<  0.01**

Changes in DBP from baseline

 LTN

−9.25 (− 11.18, − 7.32)

<  0.01**

−10.00 (− 11.93, −8.07)

<  0.01**

− 9.25 (− 11.18, − 7.32)

<  0.01**

− 9.75 (− 11.68, − 7.82)

<  0.01**

 LTN + HCT

− 10.51 (− 11.69, − 9.34)

<  0.01**

−10.33 (− 11.50, − 9.15)

<  0.01**

−10.00 (− 11.18, − 8.82)

<  0.01**

−10.89 (− 12.07, − 9.71)

<  0.01**

 N-GITS

− 12.32 (− 13.57, − 11.07)

<  0.01**

−11.74 (− 12.99, − 10.49)

<  0.01**

−11.58 (− 12.83, − 10.33)

<  0.01**

−12.21 (− 13.46, − 10.96)

<  0.01**

 N-GITS + LTN + HCT

− 16.81 (− 18.41–15.21)

<  0.01**

−16.64 (− 18.24, − 15.04)

<  0.01**

−16.90 (− 18.50, − 15.30)

<  0.01**

−16.55 (− 18.15, − 14.95)

<  0.01**

Changes in BSR from baseline

 LTN

−9.63 (− 19.87, 0.62)

0.07

−5.33 (− 15.57, 4.92)

0.31

− 11.10 (− 21.35, − 0.85)

0.03*

− 13.23 (− 23.47, − 2.98)

0.01*

 LTN + HCT

−4.96 (− 11.23, 1.30)

0.12

−7.21 (− 13.47, 0.94)

0.02*

− 10.73 (− 17.00, − 4.46)

<  0.01**

− 13.60 (− 19.86, − 7.33)

<  0.01**

 N-GITS

−11.52 (− 18.17, −4.87)

<  0.01**

− 17.08 (− 23.73, − 10.43)

<  0.01**

− 21.39 (− 28.04, − 14.74)

<  0.01**

−25.29 (− 31.95, − 18.64)

<  0.01**

 N-GITS + LTN + HCT

−13.38 (− 21.89, −4.87)

<  0.01**

− 17.62 (− 26.13, − 9.11)

<  0.01**

− 14.10 (− 22.62, − 5.59)

<  0.01**

−24.93 (− 33.44, − 16.42)

<  0.01**

Changes in Urea from baseline

 LTN

1.00 (− 0.66, 2.66)

0.24

2.35 (0.69, 4.01)

0.01*

2.03 (0.37, 3.68)

0.02*

2.65 (0.99, 4.31)

<  0.01**

 LTN + HCT

0.38 (−0.64, 1.39)

0.47

1.29 (0.28, 2.30)

0.01*

2.19 (1.17, 3.20)

<  0.01**

3.47 (2.45, 4.48)

<  0.01**

 N-GITS

−0.76 (− 1.83, 0.32)

0.17

0.71 (−0.37, 1.78)

0.20

1.39 (0.31, 2.47)

0.01*

1.81 (0.73, 2.89)

<  0.01**

 N-GITS + LTN + HCT

0.72 (−0.65, 2.10)

0.30

2.93 (1.55, 4.31)

<  0.01**

3.60 (2.23, 4.98)

< 0.01**

5.16 (3.78, 6.53)

<  0.01**

Changes in Creatinine from baseline

 LTN

0.02 (−0.03, 0.06)

0.45

0.03 (−0.02, 0.07)

0.28

0.05 (−0.001, 0.09)

0.06

0.07 (0.02, 0.11)

<  0.01**

 LTN + HCT

0.01 (−0.02, 0.03)

0.74

0.02 (−0.01, 0.05)

0.11

0.02 (−0.01, 0.05)

0.11

0.04 (0.01, 0.07)

<  0.01**

 N-GITS

−0.03 (− 0.06, 0.003)

0.08

− 0.02 (− 0.05, 0.01)

0.11

−0.04 (− 0.07, − 0.01)

0.01*

−0.04 (− 0.07, − 0.01)

0.01*

 N-GITS + LTN + HCT

−0.01 (− 0.05, 0.02)

0.47

0.01 (− 0.03, 0.04)

0.72

0.04 (0.002, 0.08)

0.04*

0.07 (0.03, 0.10)

<  0.01**

  1. Abbreviations: LTN losartan potassium, N-GITS Nifedipine GITS, HCT hydrochlorothiazide, SBP systolic blood pressure, DBP diastolic blood pressure, BSR blood sedimentation rate
  2. p-values: * ≤ 0.05, ** <  0.01
Back to article page

BMC Women's Health

ISSN: 1472-6874

Contact us